# A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

> **NCT06739213** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Runshi Pharmaceutical Technology Co., Ltd** · enrollment: 56 (estimated)

## Conditions studied

- Recurrent or Progressive High Grade Meningioma

## Interventions

- **DRUG:** SYHA1813
- **DRUG:** Investigator's Choice Treatment

## Key facts

- **NCT ID:** NCT06739213
- **Lead sponsor:** Shanghai Runshi Pharmaceutical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-01-13
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739213, "A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06739213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*